Pascal R. Hammel

37k citations
380 papers · 27.6k · 12 hit papers · h-index 77

Impact in

  • Oncology top 0.05%
    • Pancreatic and Hepatic Oncology Research
    • PARP inhibition in cancer therapy
    • Colorectal Cancer Treatments and Studies
  • Epidemiology top 0.5%
    • Neuroendocrine Tumor Research Advances

Papers in

    • Pancreatic and Hepatic Oncology Research 194
    • PARP inhibition in cancer therapy 13
    • Colorectal Cancer Treatments and Studies 10
    • Neuroendocrine Tumor Research Advances 69

Pascal R. Hammel

358 papers receiving 26.8k citations

Pascal R. Hammel's Hit Papers

Activation of lysosomal iron triggers ferroptosis in cancer 2025 · 152 citations
1520+7+14Years since publication5001k1.5k2k

Peers

Pascal R. Hammel
Comparison fields: 5 of 126
  • Oncology 16k
  • Epidemiology 3.8k
  • Surgery 3.5k
  • Hepatology 651
  • Cancer Research 968
Replace Eileen Mary O'Reilly with:
Eileen Mary O'Reilly United States
Philip B. Paty United States
David Malka France
Valérie Boige France
Juan W. Valle United Kingdom
Cristina Rosa Ferrone United States
Christian Wittekind Germany
Do‐Youn Oh South Korea
Olivier Bouché France
Antoine Hollebecque France
Pascal R. Hammel relative to Eileen Mary O'Reilly United States Eileen Mary O'Reilly's profile →
Citations per field
00.5×2×3×4.0×
Eileen Mary O'Reilly · 1×
Citations per year

Countries citing papers authored by Pascal R. Hammel

Since Specialization
Citations

This map shows the geographic impact of Pascal R. Hammel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pascal R. Hammel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pascal R. Hammel more than expected).

Fields of papers citing papers by Pascal R. Hammel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pascal R. Hammel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pascal R. Hammel. The network helps show where Pascal R. Hammel may publish in the future.

Co-authors

The 25 scholars most cited alongside Pascal R. Hammel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Pascal R. Hammel Line = papers co-authored together Pascal R. Hammel links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 380 papers — load more, or switch the sort, to bring in the rest.

#Work
1
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Hit paper breakdown →
20182184
2
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Hit paper breakdown →
20112044
3
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Hit paper breakdown →
20191784
4
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
Hit paper breakdown →
20171525
5
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
Hit paper breakdown →
2016827
6
Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial
Hit paper breakdown →
2005817
7 2008569
8
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
Hit paper breakdown →
2015565
9 2007422
10
Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study
Hit paper breakdown →
2019410
11
Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma
Hit paper breakdown →
2020385
12 2002353
13 2000349
14 2001343
15
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial
Hit paper breakdown →
2014337
16 2000311
17 2000306
18 2017284
19 2001275
20 2000253

About Pascal R. Hammel

Pascal R. Hammel is a scholar working on Oncology, Epidemiology, Surgery, Pulmonary and Respiratory Medicine and Rheumatology, having authored 380 papers that have together received 27.6k indexed citations. Recurring topics across this work include Pancreatic and Hepatic Oncology Research (194 papers), Neuroendocrine Tumor Research Advances (69 papers), Pancreatitis Pathology and Treatment (38 papers), PARP inhibition in cancer therapy (13 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (12 papers), Colorectal Cancer Treatments and Studies (10 papers), IgG4-Related and Inflammatory Diseases (10 papers) and Genetic factors in colorectal cancer (8 papers). The work is most often cited by research in Oncology (16k citations), Epidemiology (3.8k citations), Surgery (3.5k citations), Hepatology (651 citations) and Cancer Research (968 citations). Pascal R. Hammel has collaborated with scholars based in France, Belgium and United States. Frequent co-authors include Philippe B Ruszniewski, Philippe Lévy, Alain Sauvanet, Frédérique Maire, Anne Couvelard, Dermot O’Toole, Olivia Hentic, Eric Van Cutsem, Vinciane Rebours and Pierre Bernades. Their work appears in journals such as Annals of Oncology, Pancreatology, Journal of Clinical Oncology, Pancreas and The American Journal of Gastroenterology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact